The goal of adequate pain control becomes increasingly salient for children with cancer and their families as the patients approach the end of life. Methadone is one option that is particularly desirable in end-of-life care given its long duration of action and NMDA antagonism that may help in controlling pain refractory to conventional opioids. The purpose of this study was to describe a single institution’s experience with methadone for the treatment of cancer pain in pediatric end-of-life care.
Methods:
This retrospective, observational, single-center study included all patients during a 9-year period who died in the inpatient setting and were receiving methadone in their last 30 days of life.
Results:
Twenty patients were identified, 18 (90%) of whom received methadone for nociceptive pain. The median duration of methadone use was 32 days (range 2-323 days). Methadone doses ranged from 0.09 to 7.76 mg/kg per day. There were no instances of discontinuing methadone due to an increased QTc interval. No episodes of torsades de pointes were observed.
Conclusion:
In patients with pediatric cancer who are nearing the end of life, methadone is a valuable adjunctive therapy to treat nociceptive and neuropathic pain and to prevent opioid-induced hyperalgesia and opioid tolerance. An individualized approach to dosage and route should be considered based on specific clinical circumstances.
CollinsJJByrnesMEDunkelIJ, et al.The measurement of symptoms in children with cancer. J Pain Symptom Manage. 2000;19(5):363–377.
2.
DaviesDDeVlamingDHainesC. Methadone analgesia for children with advanced cancer. Pediatr Blood Cancer. 2008;51(3):393–397.
3.
HabashyCSpringerEHallEAAnghelescuDL. Methadone for pain management in children with cancer. Paediatr Drugs. 2018;20(5):409–416.
4.
PietteVBeernaertKCohenJ, et al.Healthcare interventions improving and reducing quality of life in children at the end of life: a systematic review. Pediatr Res. 2020. doi:10.1038/s41390-020-1036-x
5.
GarridoMJAguirreCTrocónizIF, et al.Alpha1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther. 2000;38(1):35–40.
6.
RipamontiCBianchiM. The use of methadone for cancer pain. Hematol Oncol Clin N Am. 2002;16(3):543–555.
7.
KristensenKChristensenCBChristrupLL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 1994;56(2):PL45–PL50.
8.
BennettGJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage. 2000;19(1 Suppl):S2–S6.
9.
JensenTS. Opioids in the brain: supraspinal mechanisms in pain control. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):123–132.
AnghelescuDLSteenBDWuH, et al.Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatr Blood Cancer. 2017;64(3):e26162.
12.
MaddenKMillsSDibajSWilliamsJLLiuDBrueraE. Methadone as the initial long-acting opioid in children with advanced cancer. J Palliat Med. 2018;21(9):1317–1321.
13.
MaddenKBrueraE. Very-low-dose methadone to treat refractory neuropathic pain in children with cancer. J Palliat Med. 2017;20(11):1280–1283.
14.
RasmussenVFLundbergVJespersenTWHasleH. Extreme doses of intravenous methadone for severe pain in two children with cancer. Pediatr Blood Cancer. 2015;62(6):1087–1090.
15.
AnghelescuDLFaughnanLGHankinsGMWardDAOakesLL. Methadone use in children and young adults at a cancer center: a retrospective study. J Opioid Manag. 2011;7(5):353–361.
16.
TsuiBCHDaviesDDesaiSMalherbeS. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol. 2004;26(10):678–680.
17.
RothMDaviesDFriebertSWangDKimMZelcerS. Attitudes and practices of pediatric oncologists regarding methadone use in the treatment of cancer-related pain: results of a North American survey. J Pediatr Hematol Oncol. 2013;35(2):103–107.
18.
MaddenKLiuDBrueraE. Attitudes, beliefs, and practices of pediatric palliative care physicians regarding the use of methadone in children with advanced cancer. J Pain Symptom Manage. 2019;57(2):260–265.
19.
ChouRCrucianiRAFiellinDA, et al.Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014;15(4):321–337.
20.
ThigpenJCOdleBLHarirforooshS. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. Eur J Drug Metab Pharmacokinet. 2019;44(5):591–609.
21.
LugoRASatterfieldKLKernSE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2009;19(4):13–24.
22.
AnghelescuDLSnamanJMTrujilloLSykesADYuanYBakerJN. Patient-controlled analgesia at the end of life at a pediatric oncology institution. Pediatr Blood Cancer. 2015;62(7):1237–1244.
23.
GjedstedJDallR. Severe hypoglycemia during methadone escalation in an 8-year-old child. Acta Anaesthesiol Scand. 2015;59(10):1394–1396.
24.
SabatowskiRKasperSMRadbruchL. Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. J Pain Symptom Manage. 2002;23(1):3–5.
25.
HabashyCAlfordELAnghelescuDLFedericoS.Rules are made to be broken: continuous methadone for intractable cancer pain. Poster presented at: 11th International Symposium on Pediatric Pain (ISPP), July 6-9, 2017; Kuala Lumpur, Malaysia.
26.
AnghelescuDLPatelRMMahoneyDP, et al.Methadone prolongs cardiac conduction in young patients with cancer-related pain. J Opioid Manag. 2016;12(2):131–138.
27.
MaddenKParkMLiuDBrueraE. The frequency of QTc prolongation among pediatric and young adult patients receiving methadone for cancer pain. Pediatr Blood Cancer. 2017;64(11):e26614.
28.
MaddenKJoEWilliamsJLLiuDBrueraE. Corrected QT interval prolongation in pediatric and young adult patients on methadone for cancer-related pain. J Pain Symptom Manage. 2019;58(4):678–684.
29.
SchwinghammerAJWilsonMDHallBA. Corrected QT interval prolongation in hospitalized pediatric patients receiving methadone. Pediatr Crit Care Med. 2018;19(8):e403–e408.
30.
AnghelescuDLHamiltonHFaughnanLGJohnsonLMBakerJN. Pediatric palliative sedation therapy with propofol: recommendations based on experience in children with terminal cancer. J Palliat Med. 2012;15(10):1082–1090.
31.
AnghelescuDLFaughnanLGBakerJNYangJKaneJR. Use of epidural and peripheral nerve blocks at the end of life in children and young adults with cancer: the collaboration between a pain service and a palliative care service. Paediatr Anaesth. 2010;20(12):1070–1077.
32.
AnghelescuDLGuoAMorganKJ, et al.Pain outcomes after celiac plexus block in children and young adults with cancer. J Adolesc Young Adult Oncol. 2018;7(6):666–672.
33.
GilSFernandez-PinedaIRaoB, et al.Role of amputation in improving mobility, pain outcomes, and emotional and psychological well-being in children with metastatic osteosarcoma. Am J Hosp Palliat Care. 2019;36(2):105–110.
34.
WolfeJGrierHEKlarN, et al.Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000;342(5):326–333.
35.
BerdeCWolfeJ. Pain, anxiety, distress, and suffering: interrelated, but not interchangeable. J Pediatr. 2003;142(4):361–363.
